The use of glial cell line-derived neurotrophic factor family-related compounds for regulating spermatogenesis and for preparing male contraceptives
CA 2338644 A1 · Owner: Hyvonen, Mervi · Inventors: Hyvonen, Mervi; Lindahl, Maria; Sariola, Hannu
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention is related to glial cell line-derived neurotrophic factor (GDNF) family-related compounds such as glial cell line-derived , neurotrophic factor (GDNF) GDNF-like factors, such as persephin, artemin and neurturin or other compounds which act like GDNF on its signal transmitting receptor, i.e. cRet receptor tyrosine kinase and/or co-receptors e.g. GDNF-, family-receptor .alpha.:s (GFR.alpha.1-4) and their use for regulating and studying spermatogenesis, for inhibting the differentiation of sperm cells for developing male contraceptives or as a male contraceptive as well as their use for manufacturing male contraceptives.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed August 20, 1999. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended August 20, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by August 20, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.